Amgen Phase III Win Positions Uplizna for Label Expansion in Rare Autoimmune Disease 6/6/2024

BioSpace x DIA: Robust Integrated Regulatory Strategies 6/6/2024

Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report 6/6/2024

Embracing Inclusivity: How Biopharmas Connect With LGBTQ+ Employees 6/6/2024

Telix Targets $200M IPO in Hot Radiopharma Market as Biotech Nasdaq Offerings Slow 6/6/2024

You’re More Than Your Job: Finding Self-Worth Outside of Work 6/6/2024

ASGCT 2024 Comes at Pivotal Time for Gene and Cell Therapy Sector 5/6/2024

Opinion: Can Ketamine Be Safely Used at Home? 5/6/2024

5 DMD Data Readouts to Watch in 2024 5/6/2024

AAVs in Focus at ASGCT: Improved Precision, Targeting Common Diseases 5/6/2024

FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment 4/6/2024

ASCO24: Novartis Leukemia Drug Beats Older Drugs in Phase III Readout 5/31/2024

Gilead’s Trodelvy Fails to Reach Primary Endpoint in Confirmatory Trial 5/31/2024

FDA Delays Dupixent Uncontrolled COPD Decision as EU Panel Recommends Approval 5/31/2024

ASCO24 Preview: A Look at Some of the Cancer Meeting’s Hottest Abstracts 5/31/2024

Smaller Biopharma M&A on Upswing, Deals Expected to Continue Through 2024 5/31/2024

BridgeBio Builds on Positive Phase III Data for Acoramidis in ATTR-CM 5/30/2024

Immunovant Shifts Focus to Other FcRn Inhibitor, Gives Rival Vyvgart Breathing Room 5/30/2024

Tris Pharma Gets FDA Approval for Non-Stimulant ADHD Medication 5/30/2024

Biohaven’s Phase I Data for Lead Protein Degrader Disappoints Investors 5/30/2024